cp-724714 and Squamous-Cell-Carcinoma-of-Head-and-Neck

cp-724714 has been researched along with Squamous-Cell-Carcinoma-of-Head-and-Neck* in 1 studies

Other Studies

1 other study(ies) available for cp-724714 and Squamous-Cell-Carcinoma-of-Head-and-Neck

Article	Year
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. Molecular pharmacology, 2019, Volume: 95, Issue:5 Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides	2019

Article

Year

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.

Molecular pharmacology, 2019, Volume: 95, Issue:5

Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides

2019